Oral Metformin for Treating Melasma in Latin American Women

Launched by UNIVERSITY OF PUERTO RICO · Feb 19, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether a medication called metformin can help reduce the dark patches on the skin known as melasma in Latin American women. The researchers want to find out if taking metformin in two different doses (500 mg and 1000 mg) can improve this condition. Participants in the study will take a daily metformin pill for three months and will visit the clinic twice: once at the beginning and once at the end of the study. Additionally, participants will receive a phone call from the research team to check on their progress and discuss any changes or side effects they may experience.

To be eligible for this trial, you must be a Latin American woman aged 21 or older who has been diagnosed with melasma. However, pregnant or breastfeeding women, those who have recently used certain skin treatments, or those with specific health conditions will not be able to participate. This is an important study, and by joining, you could help researchers learn more about potential new treatments for melasma.

Gender

FEMALE

Eligibility criteria

• • Inclusion Criteria: Latin American women aged 21 years or older, diagnosed epidermal or mixed melasma
• • Exclusion Criteria: pregnancy, breastfeeding, use of hydroquinone or tretinoin within 2 months before the study, or undergoing laser treatment, peels, microdermabrasion, or microneedling within 2 months of the study. Patients with a history of renal or liver disease, metformin allergy, diabetes, hypoglycemia, or those on medications that could interact with metformin will also be excluded.